Dopamine and frusemide in oliguric acute renal failure

G. Graziani, A. Cantaluppi, S. Casati, A. Citterio, A. Scalamogna, A. Aroldi, R. Silenzio, D. Brancaccio, C. Ponticelli

Research output: Contribution to journalArticlepeer-review

Abstract

Into 24 oliguric patients with acute renal failure (ARF) for whom mannitol and high-dose frusemide had failed to promote a diuresis, dopamine (3 μg/kg/min) plus frusemide (10-15 mg/kg/h) were infused for 6-24 h. In 19 of the 24 patients this treatment produced significant increases in diuresis (from 11 ± 7 to 85 ± 51 ml/h; p <0.001) and natriuresis (from 45 ± 13 to 88 ± 22 mEq/l; p <0.001), without any significant modification of blood pressure, pulse rate or central venous pressure. 10 of the 24 patients required dialysis: 5 because therapy failed to promote diuresis and the other 5 because of their hypercatabolic state in spite of polyuria. 5 patients died of causes unrelated to ARF. Since all patients who responded were treated within 24 h after the onset of oliguria, it appears to be crucial to administer dopamine and frusemide early, before more severe anatomical and functional damage develops.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalNephron
Volume37
Issue number1
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Dopamine and frusemide in oliguric acute renal failure'. Together they form a unique fingerprint.

Cite this